|
|||||
|
|
Cancer risk of immunosuppressants in manufacturing |
|
| Authors: | Ester Lovsin Barle Gian Christian Winkler Peter Ulrich Christopher Perino Martin Kuster Alessandro Probst Silke Thielen Rudolf Bechter |
| Affiliation: | 1. Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland;2. Novartis Pharma AG NIBR, Postfach, CH-4002 Basel, Switzerland;3. Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, United States;4. Novartis International AG, Postfach, CH-4002 Basel, Switzerland;5. Novartis Tiergesundheit AG, CH-4002 Basel, Switzerland |
| Abstract: | During the chemical and pharmaceutical production of active pharmaceutical substances which are intended for immunosuppressive therapy, the employees may be exposed to these substances via inhalation. Immunosuppressants are linked to development of certain types of cancers e.g., lymphoma or skin cancer in transplant patients. The development of these cancers in patients is linked to the level of immunosuppression needed for transplantation in order to avoid organ rejection. Below these levels, with the immune system functioning uninhibited, cancer is unlikely to develop. |
| Keywords: | Immunosuppression Occupational exposure Cancer risk Pharmaceutical production Cyclosporine |
| 本文献已被 ScienceDirect 等数据库收录！ | |